Talk:Papers

[|Transgender health: Hormonal management at 50 years and beyond. (August 2019)]

 The "Papers" page is a library of up to date research papers on subjects which you may find useful when creating articles for us, or doing your own studies.

In addition, there is also some helpful instructions on several ways to gain access to any papers you may need.


 * If you have any questions about our library you should contact our lead research librarian LilianaUmbra, who is responsible for managing research requests and this pages content.

Finding papers

 * Google Scholar indexes articles, shows citations and "cited bys", impact factor etc.
 * Pubmed offers more granular search options.

Getting access
Journal articles are frequently paywalled, requiring an obscene ~$40 per article to see anything besides their abstracts. Here's some ways around:
 * If you're a student, your university should have journal access for all IPs on its network. If you make friends with a student, you could ask to borrow their login.
 * Even if you're not a student, you can often get a library card at a university library. University library computers will have journal access, so if the library is open to the public you can surf there and save articles to a USB stick.
 * Sci-Hub is a proxy that circumvents paywalls for journal access. You can tack .sci-hub.mn on the end of the domain name for a URL you want to access. For instance, if you wanted to go to http://nature.com/some/article.html, change it to http://nature.com.sci-hub.cc/some/article.html. Note that sci-hub is frequently under attack and the legality of using it varies by region, ymmv.
 * Library Genesis has a repository of scientific papers. Unlike Sci-Hub, it does not let you access papers that don't already exist in the LibGen repository. However, it is a useful backup if Sci-Hub is down, as Sci-Hub stores a copy of every paper it downloads to LibGen.


 * Using Sci-Hub Links extension for Chrome and Firefox can be used to automatically translate DOI to sci-hub links
 * The Scholar subreddit lets you post requests for articles. Volunteers will find and upload articles for you, bypassing the paywall.
 * Arxiv hosts free pre-publication articles, but very few in the biology realm.


 * Due to the volatile nature of which domains are working for sci-hub currently, if any links are broken simply replace the domain of the link with a working one. .mn and .tw work as of 12/12/2017.

Bone Density






Hormone Replacement Therapy











 * Mad men, women and steroid cocktails: A review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors (February 2016)




 * Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals (June 2015)

Risk Analysis





 * Is Type 1 Diabetes Mellitus More Prevalent Than Expected in Transgender Persons? A Local Observation (September 2017)





Hormone Replacement Therapy





 * The Response of the Menstrual Cycle to Initiation of Hormonal Therapy in Transgender Men (October 2017)










 * Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis (February 2016)


 * High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People (October 2015)










 * Associations between transition-specific stress experience, nocturnal decline in ambulatory blood pressure, and C-reactive protein levels among transgender men (January 2012)


 * Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals (March 2010)



Genital Reassignment Surgery







 * A Longitudinal Study of Motivations Before and Psychosexual Outcomes After Genital Gender-Confirming Surgery in Transmen (November 2017)










 * Mystery and realities of phalloplasty: a systematic review (August 2017)




 * Feasibility of Vaginal Hysterectomy for Female-to-Male Transgender Men (March 2017)


 * Robot-assisted laparoscopic colpectomy in female-to-male transgender patients; technique and outcomes of a prospective cohort study (November 2016)


 * The 2011 WPATH Standards of Care and Penile Reconstruction in Female-to-Male Transsexual Individuals (May 2012)



Reproductive Health

 * Induction and Maintenance of Amenorrhea in Transmasculine and Nonbinary Adolescents (November 2017)


 * From erasure to opportunity: a qualitative study of the experiences of transgender men around pregnancy and recommendations for providers (November 2017)











Vocal Therapy








Top surgery and binding


















Hormone Replacement Therapy






Risk Analysis








Genital Reassignment Surgery














Reproductive Health




Facial Feminization Therapy






Vocal Therapy






Standards Of Care & Practice Guidelines



 * Gender incongruence: a comparative study using ICD-10 and DSM-5 diagnostic criteria (Oct 7 2017)


 * WPATH Standards Of Care 7th Edition


 * Guidelines And Protocols For Comprehensive Primary Care For Trans Clients (2015)


 * Health Care for Transgender Patients: Medical Education and Patient Access (2015)


 * Taking Charge: A Handbook For Health Care & Social Service Providers Working With Trans People (2011)


 * Gender incongruence: a comparative study using ICD-10 and DSM-5 diagnostic criteria (Oct 7 2017)

Patient Care





 * Transgender Youth: Current Concepts (December 2016)


 * Caring For Transgender Adolescents In BC: Suggested Guidelines (2006)


 * Best practices in LGBT care: A guide for primary care physicians (July 2016)

Neuroscience



 * Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals (August 2017)





















Spironolactone









 * Scalp Hair Regrowth in Hormone-Treated Transgender Woman (October 2016)





Cyproterone










Leuprolide

 * Preparation and evaluation of a phospholipid-based injectable gel for the long term delivery of leuprolide acetaterrh (June 2016)












 * A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients (July 2011)












 * Treatment with leuprolide acetate decreases the threshold of the ventilatory response to carbon dioxide in healthy males (December 2004)


 * Comparison Between a Single Dose of Goserelin (Depot) and Multiple Daily Doses of Leuprolide Acetate for Pituitary Suppression in IVF Treatment: A Clinical Endocrinological Study of the Ovarian Response(July 2002)



Bicalutamide





 * Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade (July 2016)








 * Binding of a Cyano- and Fluoro-containing Drug Bicalutamide to Cytochrome P450 46A1 (February 2015)














 * Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors (September 2007


 * Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor (May 2002)

Enzalutamide






Tamoxifen









 * The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis (June 2017)


 * Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity (March 2017)


 * Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development (December 2016)


 * Tamoxifen Resistance: Emerging Molecular Targets (August 2016)


 * Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system (August 2016)


 * Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery (August 2016)


 * Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (May 2016)


 * Tamoxifen regulation of sphingolipid metabolism—therapeutic implications (May 2015)


 * CB1 and CB2 Receptors are Novel Molecular Targets for Tamoxifen and 4OH-Tamoxifen (November 2014)


 * Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review (August 2012)



Afimoxifene

 * Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status (September 2015)


 * Synthesis and Characterizaton of Fluorescent 4-Hydroxytamoxifen Conjugates with Unique Antiestrogenic Properties (May 2010)


 * 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ (July 2001)

Toremifene





 * Sulfation of 4-Hydroxy Toremifene: Individual Variability, Isoform Specificity, and Contribution to Toremifene Pharmacogenomics (June 2012)









Endoxifen

 * Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen (October 2016)


 * Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold (September 2016)


 * Boronic Prodrug of Endoxifen as an Effective Hormone Therapy for Breast Cancer (July 2016)


 * Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies (October 2014)


 * Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells (May 2014)


 * Structure Function Relationships of Estrogenic Triphenylethylenes Related to Endoxifen and 4-Hydroxytamoxifen (April 2010)

Fulvestrant-3-boronic acid

 * Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)(October 2017)


 * Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD) (September 2016)

Raloxifene








Finasteride











 * Comparison of clinical trials with finasteride and dutasteride (September 2004)

DMRT1/SOX9 + FOXL2/WNT-4/β-catenin



 * Sexual Cell-Fate Reprogramming in the Ovary by DMRT1 (March 2015)


 * FOXL2: A Central Transcription Factor in the Ovary (February 2014)


 * Antagonistic roles of Dmrt1 and Foxl2 in sex differentiation via estrogen production in tilapia as demonstrated by TALENs (December 2013)




 * DMRT1 prevents female reprogramming in the postnatal mammalian testis (August 2011)


 * Failure of SOX9 Regulation in 46XY Disorders of Sex Development with SRY, SOX9 and SF1 Mutations (March 2011)


 * Sex determination and the control of Sox9 expression in mammals (February 2011)


 * Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter (December 2010)


 * Doublesex- and Mab-3-Related Transcription Factor-1 Repression of Aromatase Transcription, a Possible Mechanism Favoring the Male Pathway in Tilapia (March 2010)


 * Somatic sex reprogramming of adult ovaries to testes by FOXL2 ablation (December 2009)


 * Females battle to suppress their inner male (December 2009)


 * The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation (June 2009)


 * Activation of b-catenin signaling by Rspo1 controls differentiation of the mammalian ovary (February 2008)


 * Gonadal sex reversal in mutant Dax1 XY mice: a failure to upregulate Sox9 in pre-Sertoli cells (July 2005)


 * SRY, SOX9, and DAX1 expression patterns during human sex determination and gonadal development (March 2000)

Androgen Receptors

 * Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer (September 2014)


 * Androgen receptor epigenetics review article (September 2013)




 * Structure-based Virtual Screening and Identification of a Novel Androgen Receptor Antagonist (June 2012)


 * Nonsteroidal Androgen Receptor Ligands: Versatile Syntheses and Biological Data (June 2012)




 * New Selective Estrogen and Androgen Receptor Modulators (July 2010)


 * Alternative inhibition of androgen receptor signaling: Peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors (June 2010)


 * The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells (June 2007)


 * Circumventing Anti-Androgen Resistance by Molecular Design (April 2007)






 * The Corepressors Silencing Mediator of Retinoid and Thyroid Hormone Receptor and Nuclear Receptor Corepressor Are Involved in Agonist- and Antagonist-Regulated Transcription by Androgen Receptor (May 2006)




 * The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists (December 2004)


 * Androgen Regulation of the Human Hair Follicle: The Type I Hair Keratin hHa7 Is a Direct Target Gene in Trichocytes (March 2004)


 * Antiandrogen Effects of Mifepristone on Coactivator and Corepressor Interactions with the Androgen Receptor (January 2004)


 * Formation of the Androgen Receptor Transcription Complex (March 2002)

Estrogen Receptors

 * Chlorinated biphenyls effect on estrogen-related receptor expression, steroid secretion, mitochondria ultrastructure but not on mitochondrial membrane potential in Leydig cells (March 2017)


 * Molecular mechanism of estrogen–estrogen receptor signaling (January 2017)


 * Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity (December 2016)


 * A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β (August 2016)


 * Predictive features of ligand‐specific signaling through the estrogen receptor (April 2016)


 * The Molecular, Cellular and Clinical Consequences of Targeting the Estrogen Receptor Following Estrogen Deprivation Therapy (June 2015)


 * Transactivation Function-2 of Estrogen Receptor α Contains Transactivation Function-1-regulating Element (May 2015)


 * Selective estrogen receptor modulators: tissue specificity and clinical utility (August 2014)


 * Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway (July 2014)


 * In Vitro and in Vivo Molecular Imaging of Estrogen Receptor α and β Homo- and Heterodimerization: Exploration of New Modes of Receptor Regulation (November 2011)


 * High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes (May 2011)


 * A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer (May 2011)


 * Unique Ligand Binding Patterns Between Estrogen Receptor α and β Revealed by Hydrogen/Deuterium Exchange (October 2009)


 * Selective Estrogen Receptor Modulators 4-Hydroxytamoxifen and Raloxifene Impact the Stability and Function of SRC-1 and SRC-3 Coactivator Proteins (January 2004)


 * Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β (March 1999)

Aromatase

 * Ergostane-Type Sterols from King Trumpet Mushroom (Pleurotus eryngii) and Their Inhibitory Effects on Aromatase (November 2017)


 * Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies (October 2017)


 * High-Throughput Analysis of Ovarian Cycle Disruption by Mixtures of Aromatase Inhibitors (July 2017)


 * Aromatase inhibitory activity of 1,4-naphthoquinone derivatives and QSAR study (May 2017)


 * Six new ergostane-type steroids from king trumpet mushroom (Pleurotus eryngii) and their inhibitory effects on nitric oxide production (November 2016)


 * Relationship Between Breast Density and Selective Estrogen-Receptor Modulators, Aromatase Inhibitors, Physical Activity, and Diet (April 2016)


 * Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure–Function Perspective (January 2016)


 * Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors that Also Modulate Estrogen Receptors (December 2015)


 * Modulation of Aromatase by Phytoestrogens (December 2015)


 * Comparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis (September 2015)


 * Local Transformations of Androgens into Estradiol by Aromatase P450 Is Involved in the Regulation of Prolactin and the Proliferation of Pituitary Prolactin-Positive Cells (June 2014)


 * Dynamics and Flexibility of Human Aromatase Probed by FTIR and Time Resolved Fluorescence Spectroscopy (December 2013)


 * Molecular Simulations of Aromatase Reveal New Insights Into the Mechanism of Ligand Binding (August 2013)


 * Testosterone-derived estradiol production by male endothelium is robust and dependent on p450 aromatase via estrogen receptor alpha (May 2013)


 * Synthesis and Structure–Activity Relationship Studies of Derivatives of the Dual Aromatase–Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)aminomethyl}phenyl sulfamate (March 2013)


 * Development of a new class of aromatase inhibitors: Design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives (February 2012)


 * Sex Differences in Brain Aromatase Activity: Genomic and Non-Genomic Controls (August 2011)


 * Aromatase, Estrone Sulfatase, and 17β-Hydroxysteroid Dehydrogenase: Structure-Function Studies and Inhibitor Development (October 2010)


 * Diversity of mechanisms involved in aromatase regulation and estrogen action in the brain (January 2010)


 * Sequence-function correlation of aromatase and its interaction with reductase (November 2009)


 * Regulation of aromatase induction by nuclear receptor coregulator PELP1 (September 2009)


 * The Critical Iron-Oxygen Intermediate in Human Aromatase (September 2009)


 * Antiestrogen pathway (aromatase inhibitor) (July 2010)


 * Structural basis for androgen specificity and oestrogen synthesis in human aromatase (February 2010)


 * Xanthones from the Botanical Dietary Supplement Mangosteen (Garcinia mangostana) with Aromatase Inhibitory Activity (June 2008)


 * Aromatase Expression in the Ovary: Hormonal and Molecular Regulation (February 2008)

Methods

 * Self-Assembly of Stable Monomolecular Nucleic Acid Lipid Particles with a Size of 30 nm